JP2015507020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015507020A5 JP2015507020A5 JP2014557835A JP2014557835A JP2015507020A5 JP 2015507020 A5 JP2015507020 A5 JP 2015507020A5 JP 2014557835 A JP2014557835 A JP 2014557835A JP 2014557835 A JP2014557835 A JP 2014557835A JP 2015507020 A5 JP2015507020 A5 JP 2015507020A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- pharmaceutical composition
- solid tumor
- abexinostat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 12
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims 8
- 229950008805 abexinostat Drugs 0.000 claims 8
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 6
- 206010039491 Sarcoma Diseases 0.000 claims 6
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 6
- 229960000639 pazopanib Drugs 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000037844 advanced solid tumor Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 150000003840 hydrochlorides Chemical group 0.000 claims 2
- 208000037843 metastatic solid tumor Diseases 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600491P | 2012-02-17 | 2012-02-17 | |
| US61/600,491 | 2012-02-17 | ||
| US201261602544P | 2012-02-23 | 2012-02-23 | |
| US61/602,544 | 2012-02-23 | ||
| PCT/US2013/026462 WO2013123413A2 (en) | 2012-02-17 | 2013-02-15 | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015507020A JP2015507020A (ja) | 2015-03-05 |
| JP2015507020A5 true JP2015507020A5 (enExample) | 2015-04-16 |
Family
ID=48984895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557835A Pending JP2015507020A (ja) | 2012-02-17 | 2013-02-15 | ヒストンデアセチラーゼ阻害剤とパゾパニブの組み合わせおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150335609A1 (enExample) |
| EP (1) | EP2814493A4 (enExample) |
| JP (1) | JP2015507020A (enExample) |
| KR (1) | KR20140129164A (enExample) |
| CN (1) | CN104244952A (enExample) |
| AU (1) | AU2013221298A1 (enExample) |
| CA (1) | CA2864736A1 (enExample) |
| HK (1) | HK1204998A1 (enExample) |
| MX (1) | MX2014009892A (enExample) |
| RU (1) | RU2014137190A (enExample) |
| SG (1) | SG11201404888SA (enExample) |
| WO (1) | WO2013123413A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3079699A4 (en) * | 2013-12-11 | 2017-07-19 | Glaxosmithkline LLC | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| WO2017053823A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
| WO2018195446A1 (en) * | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| JP7227777B2 (ja) * | 2019-02-04 | 2023-02-22 | キヤノン株式会社 | 撮像装置 |
| KR20220018727A (ko) | 2020-08-07 | 2022-02-15 | 계명대학교 산학협력단 | 파조파닙 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물 |
| EP4255436A4 (en) * | 2020-12-07 | 2024-10-23 | HHT Foundation International, Inc. | METHOD OF TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA USING PAZOPANIB |
| EP4351734A1 (en) * | 2021-06-10 | 2024-04-17 | Teva Pharmaceuticals International GmbH | Solid state forms of abexinostat and process for preparation thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1611088T3 (pl) * | 2003-04-07 | 2009-11-30 | Pharmacyclics Inc | Hydroksamiany jako środki terapeutyczne |
| EP1755394A4 (en) * | 2004-04-16 | 2009-08-05 | Smithkline Beecham Corp | METHOD OF TREATING CANCER |
| WO2007064753A2 (en) * | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Cancer treatment method |
| CA2746085A1 (en) * | 2008-12-15 | 2010-07-01 | Eli Lilly And Company | Enzastaurin for the treatment of cancer |
| US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| WO2012103276A1 (en) * | 2011-01-26 | 2012-08-02 | Glaxo Wellcome Manufacturing Pte Ltd | Combinations |
-
2013
- 2013-02-15 JP JP2014557835A patent/JP2015507020A/ja active Pending
- 2013-02-15 SG SG11201404888SA patent/SG11201404888SA/en unknown
- 2013-02-15 US US14/377,380 patent/US20150335609A1/en not_active Abandoned
- 2013-02-15 WO PCT/US2013/026462 patent/WO2013123413A2/en not_active Ceased
- 2013-02-15 HK HK15105968.0A patent/HK1204998A1/xx unknown
- 2013-02-15 CN CN201380020595.0A patent/CN104244952A/zh active Pending
- 2013-02-15 KR KR1020147025547A patent/KR20140129164A/ko not_active Withdrawn
- 2013-02-15 AU AU2013221298A patent/AU2013221298A1/en not_active Abandoned
- 2013-02-15 EP EP13748860.7A patent/EP2814493A4/en not_active Withdrawn
- 2013-02-15 MX MX2014009892A patent/MX2014009892A/es unknown
- 2013-02-15 CA CA2864736A patent/CA2864736A1/en not_active Abandoned
- 2013-02-15 RU RU2014137190A patent/RU2014137190A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536964A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| JP2015523397A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2011079858A5 (enExample) | ||
| JP2012515184A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| JP2015502926A5 (enExample) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2018522028A5 (enExample) | ||
| JP2015527374A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| JP2015537009A5 (enExample) | ||
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| JP2014530181A5 (enExample) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2013544892A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза |